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      End of life (EOL) symptom management is the cornerstone of hospice care. Hospice patients, 
especially advanced cancer patients, have an increased need for pain and symptom management 
towards end of life. For those patients at EOL, opioids are the mainstay treatment to relieve 
intractable and breakthrough pain. Due to opioid regulatory changes over the past few years, 
there has been more confusion than clarity among the hospice & palliative care practitioners 
prescribing opioids for EOL pain management. Healthcare practices across the country are 
realigning their policies to the opioid prescription rule changes. It is imperative for hospice 
providers to translate federal and state opioid regulations into organizational policy to guide 
hospice & palliative care practice. The purpose of this project was to review, synthesize and 
reconcile federal, state, and local opioid regulations and create a system for a sustainable data 
base in order to develop and maintain opioid policies for implementation in multi-site hospice 
organization, across 35 states, to ensure ongoing compliance with opioid laws. The cyclic 
process of the KTA framework was used for the project that places creators and users within a 
system which is dynamic as well as adaptive, so that as the opioid regulations change, the policy 
and protocols will be modified and re-adopted. An umbrella opioid medication policy, and state 
specific guidance was developed. Results show that, 4 weeks after policy dissemination, 32 out 
of 35 states continued to maintain 100% clinician compliance with the umbrella opioid 
medication policy, and state specific guidance. There was a 50% reduction in opioid-related 
events. This DNP project has applicability to further compliant opioid practice in a variety of 
care settings nationwide. 
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Term  Definition 
Abuse (Opioid)  A problematic pattern of opioid use (CDC, 2019) 
Addiction (Opioid)  A major health problem characterized by increasing drug tolerance and 
compulsive urge to take opioid medication 
AVP  Assistant Vice President 
CDC  Centers for Disease Control and Prevention 
CINAHL  Cumulative Index of Nursing and Allied Health Literature 
DEA  Drug Enforcement Administration 
Diversion (Opioids)  Illegally acquiring and using opioids (CDC, 2019) 
EMR  Electronic Medical Record 
EOL  End-of-life 
HHS  The U.S. Department of Health and Human Services 
KTA  The Knowledge-to-Action conceptual framework 
MAT  Medication-assisted treatment for substance use disorders 
Misuse (Opioid)  Use of illegal drugs and/or the use of prescription drugs in a manner 
other than as directed by a doctor or using someone else’s prescription 
(CDC, 2019) 
MME  Morphine Milligram Equivalents 
PDMP  Prescription drug monitoring program 
Pill-Mill  A clinic prescribing or dispensing controlled substance drugs 
inappropriately 
RDCO  Regional Director of Clinical Operations 
SAMHSA  Substance abuse and mental health services administration 
SUD  Substance use disorder is a medical condition where use of one or 
more substances leads to a clinically significant impairment  
SUPPORT  Substance Use-Disorder Prevention that Promotes Opioid Recovery 
and Treatment (SUPPORT) for Patients and Communities Act 
SVP  Senior Vice President 
U.S.  United States 
VP  Vice President 
WHO  World Health Organization 
Withdrawal (Opioids)  Acute unpleasant symptoms caused by stopping the use of opioids 
after heavy use of few weeks or after chronic use 
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       End of life (EOL) symptom management is the cornerstone of hospice care. Hospice 
patients, especially advanced cancer patients, have an increased need for pain and symptom 
management towards end of life. Increasingly, care of advanced cancer patients, palliative or 
hospice care, is being moved to ambulatory care settings, making it even more challenging to 
manage the symptoms of dying patients .  For those patients at EOL, opioids are the mainstay 
treatment to relieve intractable and breakthrough pain. Due to opioid regulatory changes over the 
past few years, there has been more confusion than clarity among the hospice & palliative care 
practitioners prescribing opioids for EOL pain management. Healthcare practices across the 
country are realigning their policies to the opioid prescription rule changes. It is imperative for 
hospice providers to translate federal and state opioid regulations into organizational policy to 
guide hospice & palliative care practice. 
Background 
       Uncontrolled pain is one of the most debilitating symptoms at EOL which affects 50% of the 
patients in their last month of life (Dy, 2016). Pain is defined as an unpleasant sensory and 
emotional experience associated with actual or potential tissue damage, or described in terms of 
such damage (IASP, 2017). Acute pain is defined as the pain that comes on quickly, can be 
severe, but lasts a relatively short time, such as days to less than a few months. Chronic pain is 
defined as the pain that can range from mild to severe, and persists or progresses over a long 
period of time, such as over 3 months to several years. Breakthrough pain is a sudden increase in 




pain that may occur in patients who already have chronic pain from cancer, arthritis, 
fibromyalgia, or other conditions. It usually lasts for a short time, but the level of pain may be 
severe. Breakthrough pain is usually not a symptom of a new condition or a condition that has 
gotten worse. It is also called pain flare (NCI, n.d.). 
       A recent review of patient safety and end of life reports that common safety issues in 
hospice and palliative care include inappropriate pain medications and inadequate pain 
management (Dy, 2016). Hospice patients have an increased need for pain and symptom 
management towards end of life. An additional challenge, especially for hospice providers, is 
breakthrough pain in cancer patients toward end of life. This sudden eruption of severe pain in a 
patient whose pain is otherwise adequately controlled on a long-acting pain medication can 
interrupt a terminally ill patient’s daily life causing physical & psychological stress due to 
increased health burden, loss of independence and disrupted autonomy (Katz, Gajria, Shillington, 
Stephenson & Harshaw, 2017) leading to a decline in quality of life.  
       The goal of hospice is to provide comfort to the patient. Opioids are the mainstay treatment 
to relieve distressing EOL symptoms, such as intractable nausea and vomiting, dyspnea, cancer 
pain, and delirium. In a systematic review(Brant, Rodgers, Gallagher, & Sudaramurthi, 2017), it 
was found that opioids are the most effective and safe evidence-based pharmacologic treatment 
for adequate management of breakthrough cancer pain. Opioids are a substance used to treat 
moderate to severe pain. Opioids are like opiates, such as morphine and codeine, but are not 
made from opium. Opioids bind to opioid receptors in the central nervous system and block pain 
messages from body to the brain (NCI, n.d.). In spite of increasing regulatory scrutiny of opioid 
prescriptions and use, opiates are desirable and effective options for managing physical pain in 
terminally ill patients (Albert, 2017).  





History of Opioid Prescription in United States 
 
       Pain treatment in the United States (U.S.) has evolved over the years. In later part of the 19th 
century morphine was used to treat pain symptoms in those injured in Civil War. Similarly, 
anesthetics and analgesics were prescribed to manage pain in war veterans during early 20th 
century (Bernard, Chelminski, Ives, & Ranapurwala, 2018). In the last 50 years, the U.S. has 
seen a progressive increase in opioid prescriptions.  During the 70s, physicians were trained to 
order minimal opioids for pain, and nurses were trained to give minimum dose of prescribed 
opioids, often less than the prescribed dose. Unless death was imminent, a patient’s pain was 
undertreated and poorly managed. In the following decade, studies done on small groups of 
patients, mainly inpatient, suggested use of opioids for pain control in chronic cancer and non-
cancer patients. These studies deemphasized the risk of addiction to prescription opioids. There 
was no long-term study of effects of opioids and no published data on use of opioids for chronic 
pain (Meldrum, 2016). Around the same time, World Health Organization (WHO) recommended 
opioids for treating cancer pain and for pediatric chronic noncancer pain (Scholten, Christensen, 
Olesen, & Drewes, 2019).  
       By the 1990’s there was a rise in opioid prescriptions. Controlled substances were ordered 
not only to manage acute pain after surgery, pain in advanced cancers and pain in patients who 
were terminally ill, but also to manage intractable and chronic pain. In the same decade, 
pharmaceutical companies caught on to the idea of mass producing and promoting opioids. There 
was a widespread perception that prescription opioids were not addictive. Due to the American 
Pain Society’s designation of pain as the fifth vital sign and recommendation to physicians to 
aggressively manage patient’s pain, the physician practices experienced a surge in opioid 
prescriptions. The health insurance companies provided good coverage of patient’s opioid 




prescription but rather poor coverage of non-pharmacologic approaches to pain management, 
such as physical therapy. Lack of health insurance coverage led to more patients using opioid 
prescriptions to manage pain (DeWeerdt, 2019). 
       As the movement to manage pain better gained momentum, the sale of prescription opioids 
increased in the 1990s, and quadrupled between 1999 to 2010. There was an increase in non-
prescription and illegal opioid use seen parallel to the prescription opioid increase (Bonnie, 
Schumacher, Clark, & Kesselheim, 2019). Drug companies, such as Purdue Pharma, did 
aggressive marketing of opioids as safe for long-term use. Due to abundant opioid prescriptions, 
there was an increase in scheduled substances available to the public in their homes, which 
resulted in misuse, drug diversion and illegal sale. An increasing number of patients became 
addicted to opioids and there was an increase in drug-seeking behavior. Patients changed 
providers, pharmacies, and sometimes their hometown to gain a prescription for opioids, either 
for personal use or to sell on the streets for a higher price. Those who could no longer afford or 
were denied a prescription, took to drug traffickers and cheap street drugs to fulfil their addiction 
needs. The years 2000-2014 saw an alarming 137% increase in controlled substance overdoses 
and a 200% increase in overdose deaths (Meldrum, 2016).  
Opioid Guidelines in the United States 
       Mild to moderate pain can be effectively managed with non-opioid analgesics, however 
stronger pain medications are needed to manage severe pain. Many cancer patients live with 
moderate to severe pain throughout their life, either due to nature of their disease or due to long-
term effects of cancer treatment. Cleary, Gelband and Wagner (2015) explain that cancer pain 
equally affects the rich and the poor, especially toward the end of life. So, the use of “opioids—
such as codeine and morphine—are invariably needed toward the end of life” (Cleary, Gelband, 




& Wagner, 2015, p. 166). Because of this, international and national guidelines and 
recommendations continue to vouch for a need of opioids to manage cancer and terminal pain. 
       The World Health Organization (WHO) recommends opioid agonists for moderate to severe 
cancer pain. Opioid medications such as morphine have been included in the WHO Model List 
of Essential Medicines for adults since 2002, and for children since 2007 (WHO, September, 
2019; WHO, 2019). Additionally, to treat pediatric patients, “several other opioid agonists are 
included in the WHO Guidelines on the Pharmacological Treatment of Persisting Pain in 
Children” (Duthey & Scholten, 2013, p. 284). Effective pain and symptom control in end-of-life 
care can allow patients to progress through the dying process in a safe, dignified, and 
comfortable manner. The Centers for Disease Control and Prevention (CDC) released guidelines 
for prescribing opioids to treat chronic pain outside of active cancer, palliative, & end-of-life 
care. The CDC defines chronic pain as a condition lasting more than 3 months or past the normal 
healing of tissue injury. The purpose of these guidelines is to improve opioid prescription 
practice for safe and effective pain treatment, and to reduce harm to the patient (CDC, 2019). 
       Similarly, the U.S. Department of Health and Human Services (HHS) recommends and 
offers opioid & pain management education for medical professionals. HHS recognizes medical 
professional’s role in safe prescription and management of opioids. When prescribing opioids, 
HHS recommends assessing risk to the patient, educating patients, and co-prescribing naloxone. 
Naloxone is an “opioid-antagonist” that is used to treat opioid overdose. It is used to “counteract 
life-threatening depression of the central nervous system and respiratory system” (Harm 
Reduction Coalition, n.d., para 1) so that person can begin to breathe normally. If administered 
on time, naloxone can temporarily reverse opioid effects and prevent overdose death (SAMHSA, 
2018).  




      The National Hospice & Palliative Care Organization, National Association for Home Care 
& Hospice, and American Academy of Hospice and Palliative Medicine continue to emphasize 
importance of pain management in palliative and EOL patients. Additionally, these national 
organizations recommend and offer continued training and education to medical professionals on 
pain management, safe opioid prescribing, and opioid risk mitigation when prescribing opioids to 
patients during palliative and EOL care. 
Problem Statement 
       The current state of the opiate epidemic has caught regulators’ attention. There has been 
development of new federal and state-level interventions to guide opioid prescription and 
disposal practice. During site surveys, hospice accrediting bodies, and federal and state surveyors 
specifically review hospice operations’ compliance with those rules. To assure safe opioid 
treatment to patients, and to stay compliant with federal and state regulations, hospice operators 
must align their policies with national and local rules. As per the WHO 2018 report, “clinical and 
policy guidelines should be complementary in order to increase overall access to controlled pain 
relief medicines” (WHO, 2018, p. 23). There are federal as well as state opioid regulations. 
However, state opioid regulatory changes are not standardized across all state lines. Hospice 
providers need a detailed review of federal and state-level opioid regulations and practice rules to 
develop or revise opioid prescription and disposal policies and protocols. There was no one 
professional society, organization, website, or hospice practice that has federal and all U.S. 
state’s opioid regulatory data. An opioid regulation and practice rule data repository was needed 
to house the federal and state rules at one central location. The data was collected from literature 
review, professional and national organizations, and federal and state legislatures. This 
regulatory data repository can provide ready access to federal and state opioid rules and 




regulations for a systematic review. A detailed review of this regulatory data can help develop an 
opioid policy for hospice clinicians. This opioid policy can further inform hospice practice 
protocols for standardization of care. Implementation of informed policy and protocol can assure 
regulatory compliance and medico-legal fortitude for a multi-state healthcare organization. 
Significance of Addressing the Problem 
       Healthcare in the United States is complex and heavily regulated. Hospice practice is no 
exception. Federal and state authorities publish rules and directives that guide health industry 
operations and impact clinical practice. The Centers for Medicare and Medicaid, the Health 
Insurance Portability and Accountability Act, the United States Drug Enforcement 
Administration (DEA), and the U. S. Food and Drug Administration are a few of the many 
federal regulatory authorities impacting hospice practice. In addition, each state may have 
hospice rules, drug rules, and state practice acts that guide hospice operations. To develop policy 
and practice protocols, a multi-state hospice organization needs to review federal as well as state 
guidelines across the state lines. Hospice providers have to sift through this web of rules and 
regulations to provide safe and compliant patient care.  
      The nation is currently going through a major opioid epidemic. Providers across the country 
are trying to keep up with the changing landscape of federal and state opioid rules. Hospice 
providers (physicians and nurse practitioners) prescribe opioids to hospice patients and monitor 
patients for pain and symptom relief. A lack of a central opioid regulation repository makes it 
cumbersome and challenging to search through a myriad of resources to develop an informed 
policy. That’s why developing an opioid regulatory catalog containing the most pertinent and 
relevant rules and statutes is the first logical step toward an informed organization-wide policy. 
Also, currently there’s no review of opioid rules and regulations literature available for 




systematic policy development. That’s why a thorough review of opioid regulations and statutes 
is the next logical step in policy development. A qualitative analysis of opioid rule data will 
identify opioid guideline themes in favor of, neutral to, or not in favor of hospice practice. The 
themes will guide the development of hospice policies and practices for the prescribers. To 
comply with federal and state opioid regulatory requirements, an up-to-date policy can be a 
reliable source to guide development of clinical practice protocols. A lack of federal and state 
opioid regulations review may misinform policy development, cause noncompliance with 
published rules, risk regulatory authority scrutiny, and compromise patient care.  
 
  





Review of the Literature 
       A review of the literature for current state of opioid regulatory changes and policies to guide 
safe patient practices was conducted (Appendix A). A search was conducted using the 
Cumulative Index of Nursing and Allied Health Literature (CINAHL), PAIS Index, and Ovid 
Medline databases using the following keywords: end of life, palliative care, hospice, pain 
management, cancer pain, opioid, policy, rules, standards, recommendations, practices, 
prescribe, overdose, addiction, naloxone, toolkit, and repository. In addition to the keywords, 
three Boolean operators were used for the search: and, or, and not. The search yielded 419 
scholarly articles of which 19 were reviewed. Articles supporting evidence for opioids used in 
end of life and cancer pain were included in the review. Literature was excluded if the article did 
not include opioid use in pain management.  
      Resources also included relevant federal, state, and local agencies and professional 
organizations for guidelines, such as the Centers for Disease Control and Prevention, the 
International Association for the Study of Pain, the National Conference of State Legislators, the 
National Science and Technology Council, the National Cancer Institute, the Prescription drug 
abuse policy system, the Substance Abuse and Mental Health Services Administration , the U.S. 
Department of Health and Human Services, and the World Health Organization. The literature 
review provided insight into the current opioid crisis in the United States, and federal and state 
strategies to address this opioid crisis. 
Current Opioid Crisis 
       The beginning of the 21st century saw a rise in strategies to better manage pain in 
Americans, including recognizing pain as the fifth vital sign. In the year 2000, Veterans’ Health 




Administration established protocols throughout the system to routinely screen and assess pain in 
patients. The strategy was that patients were not to be denied analgesics due to fear of addiction 
or side effects. In 2001, the Joint Commission released pain management accreditation standards 
for ambulatory, inpatient as well as home care providers. The standards recognized and 
recommended that pain assessment and management is a patient’s right. This was a paradigm 
shift towards accepting patient’s subjective reporting of pain over the ill effects of opioids. The 
physicians found failing to adequately treat a patient’s pain were disciplined, fined, or 
sanctioned. Medical boards were addressing complaints of inadequate prescribing to manage 
patient’s pain and, in litigation against physicians undermanagement of patient’s pain was 
considered neglect. In 2004, the Federation of State Medical Boards policy advised state medical 
boards that overtreatment and undertreatment of pain were both equally considered a violation of 
the standard of care (Garcia, 2013).  
       As the philosophy of pain management and perception of painkiller prescriptions shifted, the 
quantity of prescription opioids sold to pharmacies, hospitals, and medical clinics steadily and 
sharply increased between 1999 and 2010. The health insurance payors saw a cost saving in 
restricting reimbursement for non-pharmacologic interventions for pain management, such as 
physical therapy, cognitive-behavioral therapy, and complementary and alternative medicine 
(Tompkins, Hobelmann, & Compton, 2017). The number of pain management clinics focusing 
on pain treatment through opioid prescription increased and primary care practitioners prescribed 
opioids without education or warning patients of the risk of addiction. The increased use of 
prescription controlled substances led to abundant availability of opioids in the community. This 
in turn led to a rise in opioid misuse, abuse, diversion, nonmedical use, and overdoses. The 
opioid addicted nonmedical users turned up at emergency departments to fulfill their needs. The 




nonmedical prescription opioid use is costing American insurers approximately $72.5 billion 
annually (Garcia, 2013). Those who couldn’t afford a prescription painkiller took to the streets to 
buy cheaper versions of the opioids. This gave rise to an illicit drug market where drug-
traffickers reached the American middle-class (Meldrum, 2016).  
       The United States is thus facing an opioid crisis caused by opioid practices from the past 
three decades. The opioid epidemic has equally impacted all ages, gender, and every 
socioeconomic group in the United States (Bonnie, Ford, & Phillips, 2017). No corner of the 
country is untouched by the ill effects of the opioid epidemic.  
 
Figure 1. Drug Overdose Deaths in the U.S. Involving Opioids, 1999 to 2018. Source: National 
Center for Health Statistics WONDER (1999-2016) and Provisional Drug Overdose Death 
Counts (2017-2018), National Vital Statistics System, Mortality, National Science & Technology 
Council. Retrieved from https://www.whitehouse.gov/wp-content/uploads/2019/10/Health-
Research-and-Development-for-Opioid-Crisis-National-Roadmap-2019.pdf December 2019. 
 




       Between 1999 and 2010, the number of opioid prescriptions sold quadrupled and 
prescription painkiller overdose deaths tripled. By 2018, the overdose deaths from prescription & 
illicit opioid use had reached 42,250, an alarming level of five times the 8,050 overdose deaths in 
the year 1999 (NSTC, 2018) (Figure 1). Meldrum (2016) brings attention to “an alarming 
increase in heroin use across the country and an epidemic of drug overdose deaths, which 
increased 137% between 2000 and 2014; overdoses involving prescription opioids and heroin 
increased 200% in that period” (p. 1366). Children born to opioid users experienced opioid 
withdrawal. The opioid crisis had now extended from families to communities in the United 
States (NSTC, 2018). In 2017, under President Trump’s direction, HHS Secretary Eric D. 
Hargan declared the opioid crisis a public health emergency in the U.S. (HHS, 2017).   
Federal Strategies to Address the Opioid Crisis 
 
       CDC recognizes that long-term opioid use in noncancer nociceptive and neuropathic pain 
presents a serious risk to the patient and adds the burden of managing the prescription use to the 
primary care practices. In 2016, the CDC released opioid guidelines for primary care providers. 
In the guidelines, the CDC has opioid prescribing recommendations to treat chronic pain in 
outpatient settings. The rationale of these guidelines is to improve primary care provider 
knowledge and opioid prescribing practices to safely manage patient’s pain in an outpatient 
setting. The CDC guidelines clarify that active cancer treatment, palliative care, and end- of-life 
care opioid prescribing is excluded from these guidelines (Dowell, Haegerich, & Chou, 2016). 
The CDC released an advisory statement in April 2019 clarifying the scope of application of 
2016 CDC opioid prescription guidelines. The guidelines are not intended for patients in active 
cancer treatment, patients experiencing acute sickle cell crises, patients experiencing post-




surgical pain, patients who already prescribed a higher dosage (≥90 MME/day) of opioids, or for 
use in patients on medication-assisted treatment for opioid use disorder (CDC, 2019). 
       On March 19, 2018, President Trump declared his plan to fight the opiate crisis with priority 
to “improve access to prevention, treatment, and recovery support services; target the availability 
and distribution of overdose-reversing drugs; strengthen public health data reporting and 
collection; support cutting-edge research on addiction and pain; and advance the practice of pain 
management” (HHS, 2017, para 7). As a result, Congress funneled more funds in the fiscal year 
2019 budget to assist federal, state, and community organizations to combat the opioid crisis 
through opioid addiction prevention and treatment programs; overdose, reversal, and recovery 
policies; and research and development. This funding can expand coverage through the 
Affordable Care Act to assist in increasing existing addiction treatment benefits for the uninsured 
(Hahn, 2018). The changes in federal policy have fueled initiatives to address and drastically 
change current opiate treatment projects and policies for both practitioners and patients. The 
interventions for patient safety include Centers for Disease Control guidelines for prescribing 
opioids for chronic pain, Prescription drug monitoring programs (PDMPs), naloxone for opiate 
overdose emergencies, and expansion of medication assisted treatment (MAT) (Painter, 2017; 
McGinty et al., 2018).  
       The Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for 
Patients and Communities Act or the SUPPORT for Patients and Communities Act was enacted  
in 2018. Despite differences among Democrats and Republicans on many policies of national 
interest, the SUPPORT for Patients and Communities Act received bipartisan support. Under 
SUPPORT for Patients and Communities Act, there are provisions to address the opioid crisis 
and patient safety for Medicaid, Medicare, and other health insurance enrollees, including mental 




health parity for substance use disorder (SUD), safe disposal of unused medication provision for 
hospice providers, provisions for emergency departments, empowering pharmacists and 
prescribers by developing opioid prescribing and dispensing best practices. The act has 
provisions for grants for peer support communities of recovery and regional centers for SUD 
education (S. 2680, 2018).  
       Additionally, under the SUPPORT Act, there is a provision for expansion of existing 
programs to address the opioid crisis – expanding access to telehealth and federal reimbursement 
for SUD, incentives for prescribing opioid alternatives, and empowering the providers to use 
MAT for effectively treating SUD and sustaining recovery (McCullough, 2018). Successful and 
uniform implementation of the Mental Health Parity and Addiction Equity Act, and its alignment 
to evidence based federal, state, and community level opiate treatment programs depends on – 
collaboration and communication among stakeholders and agencies, creation and standardization 
of education materials and clinical tools, and state evaluation of the practices and operations of 
an insurer (Painter, 2017). 
       In the Substance Abuse and Mental Health Services Administration (SAMHSA) opioid 
overdose prevention toolkit, one of the strategies recommended to prevent overdose death is 
ensuring ready access to naloxone. Naloxone is not an addictive medication and thus has no 
abuse potential; it only works in the body if an opioid is present otherwise it has no effect on the 
body. Another benefit of naloxone is that it can be injected or administered intranasally with 
equal ease either by trained medical professional or by layperson.  





Figure 2. Does the jurisdiction have a naloxone access law? Reprinted from National institute on 




       Ease of use makes it an ideal medication to use in a prescription opioid as well as heroin 
overdose (Harm Reduction Coalition, n.d.). Moreover, it is available at pharmacy stores at low or 
no cost (SAMHSA, 2018). The national naloxone initiative to reverse an opioid overdose is 
currently operating in all 50 states and supports the use of naloxone for opiate overdose 
emergencies (SAMHSA, 2017) (Figure 2). 
State Strategies to Address the Opioid Crisis 
 
       State regulatory bodies are addressing the opioid overdose crisis through policy and 
regulatory efforts. State legislators establish regulations, and state regulatory bodies such as, the 
health department or the state licensing authority, implement and enforce those regulations. 
States are addressing opioid overdose issues, inappropriate opioid prescription issues, and safe 
opioid prescribing by establishing prescription drug monitoring programs (PDMPs), regulating 




pain clinics, and establishing opioid dosage thresholds (Garcia, 2013). Also, states are addressing 
the complexity of the opioid crisis by imposing regulatory requirements in addition to enforcing 
federal laws (Garcia, 2013). 
            Prescription drug monitoring programs. PDMPs are state administered centralized 
electronic databases to track opioid prescriptions. The database enables prescribers and 
pharmacies to screen and monitor history of patient’s prescription medication use. The database 
facilitates recognizing potential prescription medication abuse or diversion. PDMPs empower 
state regulatory bodies to monitor prescribers inappropriate prescribing and pharmacies 
inappropriate dispensing behaviors.  
        
Figure 3. Does this state have legislation authorizing a PDMP? Reprinted from National institute 




       Currently, 49 states and District of Columbia have mandatory PDMP laws (Figure 3). The 
state of Missouri is the only state that has not been able to pass the PDMP bill through its state 




senate seven years in a row (Howell, 2017; Weber, 2019). The mandatory PDMP enrollment law 
requires prescribers and pharmacies to enroll in to access the database. In addition, the 
mandatory PDMP query laws require prescribers and pharmacies to check their state’s PDMPs 
prior to prescribing opioids. PDMP law prevents doctor shopping and rogue physician 
prescribing practice (Painter, 2017; McGinty et al., 2018; Garcia, 2013).  
           Regulating pain clinics. As shown in figure 4 below, as of May 2018, 12 states have 
enacted some kind of pain management clinic law (PDAPS, 2019) (Figure 4). These laws 
regulate the clinic’s protocols, physician prescribing practices, and owner accountability. 
 
Figure 4. Is there a pain management clinic law? Reprinted from National institute on drug 
abuse’ Prescription drug abuse policy system (PDAPS). Retrieved from 
http://pdaps.org/datasets/pain-management-clinic-laws December 2019. 
 
       The difference between a legitimate pain management clinic, and a “pill-mill” pain clinic is 
their prescription practice. The pain management clinics treat and manage patient’s chronic pain 
and prescribe a controlled substance to the majority of their patients. These clinics have a 
licensed physician trained in safe pain management practices providing oversight to the program. 




The other licensed providers at these clinics are also trained in safe pain management practices, 
including recognizing signs of addiction & diversion. These clinics are usually affiliated with a 
hospital or a larger health care system. The “pill-mill” pain clinics, on the other hand, are mostly 
run by private owners who are not medically trained. The purpose of these clinics is maximizing 
patient volume to maximize profit. These clinics do not institute legitimate pain management 
practice, operate cash-only, refer all their patients to one diagnostic facility, and prescribe 
identical opioid prescription to all patients. (Garcia, 2013).  
           Establishing Dosage Thresholds. Since the release of CDC opioid guidelines in 2016, 
states have been considering opioid policy revisions. As of October 2018, >30 states have 
enacted laws setting limits on opioid prescriptions. The CDC guidelines for prescribing opioids 
recommend cautious opioid prescription dosages for safe and more effective pain treatment. 
Prescribing lowest effective dosage and titrating up or tapering down based on individual 
benefits helps keep a close watch on the patient. The CDC recommendation is to weigh in 
individual risk when increasing dosage to ≥50 morphine milligram equivalents (MME)/day, and 
to avoid increasing dosage to ≥90 MME/day. However, the guidelines recommend that the 
clinician should carefully consider rationale & effects if dosage needs to be titrated to ≥90 
MME/day (CDC, 2019).  
       To control the quantity of opioids prescribed and dispensed in the community, states have 
enacted laws restricting opioid prescription to a certain number of days of supply (Figure 5). 
These restrictions are mostly for first-time opioid prescriptions and allowed number of days of 
supply ranges from 3 days to 14 days. Some states specify that these restrictions are for 
managing acute pain, and provide exceptions for chronic, cancer, palliative, and hospice patients. 




Many state laws have provisions to allow for exceptions for patients who are receiving 
medication-assisted treatment (MAT) for substance-use disorder (SUD) (NCSL, 2019).  
 
 
Figure 5. Laws setting limits on certain opioid prescriptions. Reprinted from National conference 
on state legislatures (NCSL). Retrieved from http://www.ncsl.org/research/health/prescribing-
policies-states-confront-opioid-overdose-epidemic.aspx  December 2019. 
 
       In addition to setting initial opioid prescription limits for adult patients, Alaska, Connecticut, 
Indiana, Louisiana, Massachusetts, Nebraska, Pennsylvania and West Virginia have also set 
opioid prescription limits for minors. Additionally, these state regulations require opioid 
education, including discussing opioid risks and side effects, with minor patients and their adult 




caregivers. In contrast, states such as New Hampshire, Ohio, Oregon, Vermont, Virginia, 
Washington and Wisconsin have not enacted the opioid prescription limit statute. They direct 
other state regulatory authorities, such as the health department or board of medicine to institute 
opioid prescribing limits (NCSL, 2019). 
       “Overdose Good Samaritan” immunity laws related to naloxone use protect drug users who 
call for emergency assistance in the event of a drug overdose and may seek addiction recovery 
treatment after naloxone administration. Access to naloxone for overdose reversal is dependent 
on state policies which are not aligned across all states, and not all of the states have passed 
overdose Good Samaritan Law (PDAPS, 2019; SAMHSA, 2017) (Figure 6). 
 
 
Figure 6. Does the jurisdiction have a drug overdose Good Samaritan Law? Reprinted from 
National institute on drug abuse’ Prescription drug abuse policy system (PDAPS). Retrieved 
from http://pdaps.org/datasets/good-samaritan-overdose-laws-1501695153 December 2019. 
 




       While Overdose Good Samaritan immunity laws vary by state, they all consider either 
decriminalizing or mitigating actions for possession and use of drugs (SAMHSA, 2017). 
Enactment of this law is a step towards lifting the stigma and changing the thought process that 
opioid misuse is a choice. Also, separating the drug user laws from drug seller laws is 
appreciated by lawmakers and the public. Spotlight on the opioid misuse issues has changed 
policymakers’ perceptions and fostered an understanding that opioid misuse is a medical 
condition in need of treatment (Johnson, 2018; Saunders, Jarlenski, Levy, & Kozhimannil, 
2018).  
       Along with instituting new opioid policies, states have revised and remodeled existing laws 
and policies (Parker, Strunk, & Fiellin, 2018). On a community level, syringe exchange 
programs are one such comprehensive strategy to address the health of people with SUD. 
Currently, 41 states have syringe exchange programs. These programs promote prevention of 
drug-related transmission of infections by providing access to free sterile syringes and needles, 
and safe disposal of used syringes and needles. Syringe exchange programs are providing much 
needed resources for the community by targeting high-risk areas (Painter, 2017). Reforms in 
opioid prescribing practices will help prevent substance abuse, diversion and overdose, while 
ensuring legitimate access to pain management. Opioid prescribing cap laws limit the number of 
days’ supply and/or dose of prescribed opioids. Pill mill laws strictly regulate pain management 
clinics to prevent rogue clinics (pill mills) from issuing opioid prescriptions without medical 




       Since the 2016 release of CDC opioid prescription guidelines, there has been a flood of 
opioid related laws and policies being enacted at the federal as well as the state level. These 




opioid prescription laws are not uniform across all the states, and not all states have an opioid 
prescription law. Most federal and state opioid regulations have provisions to exempt cancer, 
palliative care and hospice patients, but not all. While bipartisan efforts to curb the opioid 
epidemic continue at all levels, disparity remains among states regarding opioid policies (Painter, 
2017). Fear surrounding inappropriate use of opioids and an increase in opioid related 
regulations have caused unintended consequences for the hospice patients (Fehlberg, Broyles, 
Wu, & Halpern, 2018). Due to fear of being scrutinized by the state regulatory authority or a 
state professional board, physicians are prescribing minimum dosage of opioids. By prescribing a 
minimum dosage, the prescriber doesn’t have to deal with opioid risk mitigation required when 
prescribing higher dosage of opioids to the patient.  Even when the controlled substance is 
prescribed to a hospice patient, pharmacies in many states are restricting quantity of medication 
dispensed to the minimum number of days allowed by the state law. Hospice patients need 
opioids for pain relief from advanced illness and hospice practitioners need to be knowledgeable 
of opioid regulations to abide by the law and to provide care without delay. Hospices need to 
review opioid regulations and create policies for opioid use in inpatient and home-hospice 
setting. A review of current opioid regulations and development of opioid prescription, use, and 
disposal policies and practices will provide clarity to hospice and palliative care practitioners 
engaged in care of EOL advanced cancer and non-cancer patients. These policies will guide the 
hospice clinicians of their role and responsibility while caring for patients who are prescribed 
opioids at EOL. This exercise will also advise hospice & palliative care practices to comply with 
federal & state opioid regulations. 
Theoretical Framework 




      The Knowledge-to-Action (KTA) Process Framework (Figure 7) is a theoretical framework 
in evidence-based implementation of knowledge into action. Graham et al. (2006) proposed the 
KTA process conceptual framework to encourage use of research knowledge by a variety of 
stakeholders in healthcare, from bedside clinician to boardroom executive. The KTA process has 
two components: (1) knowledge creation and (2) action. Each component consists of several 
phases on which the model continues to build. KTA is a dynamic and complex process, where 
 
 
Figure 7. The Knowledge-to-Action Framework (KTA Framework). Reprinted from The 




Knowledge-to-Action Framework. Retrieved from https://medium.com/knowledgenudge/kt-101-
the-knowledge-to-action-framework-7fbe399723e8 October 2019 
the framework knowledge creation process can be applied into action for long-term 
sustainability. The two components have several sequential or simultaneous phases. These 
phases are contained in a cyclic model to allow for a constant feedback loop. 
       The knowledge creation component consists of knowledge inquiry, knowledge synthesis, 
and knowledge tools to tailor into creating knowledge for action. It is shaped as an inverted 
funnel to gather several pieces of knowledge and filter the most applicable and refined 
knowledge toward the action component. The knowledge built is moved into the next 
component, action. Action has a series of phases that include adapting the knowledge, 
implementing in the setting of choice, monitoring knowledge use and evaluating outcomes. 
Barriers and facilitators to the implementation process are addressed within the action 
component as well. Evaluating outcomes of the process during an action component helps 
determine the impact of the knowledge gained on practitioner practices, patient care outcomes, 
and the healthcare system. Graham et al. (2006) recommend creating a knowledge sustainability 
plan that can withstand system changes. 
Applicability:  
      The KTA Process Framework aligns with the scope and purpose of this project, which is to 
synthesize accumulated opioid laws and regulation knowledge into actionable system-level 
policy for hospice practice and evaluate consistent use of the policy by hospice care practitioners 
(Figure 8). The cyclic process of the KTA framework places creators and users within a system 
which is dynamic as well as adaptive. The policies created as a result of opioid regulation 
synthesis will be adopted for use by hospice physicians, nurse practitioners, and nurses. The 
policy will inform clinical practice protocol development. As the opioid regulations change, the 




policy and protocols will be modified and re-adopted. The policy built will be relevant, 
applicable, and intuitive for hospice practitioners’ daily use. Potential barriers and facilitators to 
policy implementation and adoption need to be considered before implementing the policy. To 
help facilitate systemwide implementation, effective adoption, and continued compliance with 
the policy, change champions need to be identified. The desired outcome of this project is 
system-wide successful policy implementation and adoption.  
 
Figure 8. The KTA Framework Applicability.  




Organizational Description & Analysis 
       Amedisys, Inc. is a for-profit healthcare at home company delivering personalized home 
health, hospice and personal care, with the corporate office located in Baton Rouge, Louisiana, 
and the executive office located in Nashville, Tennessee. Amedisys’ mission is to honor those we 
serve with compassionate home health, hospice, and personal care services that apply the highest 
quality clinical practices toward allowing our patients to maintain a sense of independence, 
quality of life and dignity (About Amedisys, 2019). Amedisys provides in-home skilled nursing, 
physical therapy, occupational therapy, speech language pathology, medical social work, home 
aides, respiratory therapist, music therapist, life enhancement specialist, massage therapist and 
hospice and bereavement services. Amedisys employs approximately 16,000 individuals at more 
than 500 locations in more than 40 states, for providing home health, hospice and personal care 
services. 
      Amedisys Inc. (Nasdaq: AMED) recently became the third-largest hospice provider in the 
United States. Acquiring Compassionate Care Hospice in the year 2019 propelled Amedisys 
companywide into the new markets of Michigan, South Dakota, Minnesota and Nebraska, while 
also expanding its presence in Texas. Also, this acquisition allows Amedisys to offer a full 
continuum of care in Florida. In addition, the company acquired RoseRock Healthcare in April 
2019, Asana Hospice in January 2020, and Aseracare Hospice in June 2020. Amedisys’ post-
acquisition hospice operations include 190 care centers in 35 states with an average daily census 
of about 12,000 patients. The idea is that by better managing beneficiary populations as they age 
in place and reach the end of life, these integrated providers can help keep costs down and 
quality high (Holly, 2018).   




      Since Amedisys operates multi-site hospice practice in 35 states, a review of federal and each 
state’s opioid rules corresponding to hospice practice was needed for Amedisys’ global 
medication management policy. This DNP project developed an opioid rule database, cross-
referencing federal and state opioid rules and corresponding hospice guidelines. Amedisys’ 
clinical services, operations, legal, and quality departments collaborated for this project. A 
consult with external counsel was sought as needed. The project is timely and relevant to the 
organization’s growing multi-state operations and the aims of the project are aligned with the 
needs of the organization.  
  






       The goal of this project was to develop opioid use policy specifically for a multi-state 
hospice practice and ensure Amedisys hospice care centers within 35 states adhere to the federal, 
state, and local opioid regulations.  This was accomplished by downloading federal, state, and 
local opioid regulations and creating a repository. The downloaded regulations were appraised to 
create policy themes including opioid prescription, opioid use, opioid disposal, and opioid 
education. The regulations under those major policy themes were synthesized to create an opioid 
policy for hospice practice. This policy was implemented system-wide, and an evaluation of 
clinician’s successful adherence to the policy was conducted. 
Goal: Review, synthesize and reconcile federal, state, and local opioid regulations and create a 
system for a sustainable data base in order to develop and maintain opioid policies for 
implementation in care centers across 35 states to ensure ongoing compliance with opioid laws  
by a multistate provider.  
Aim 1: Create a repository of federal, state, and local opioid regulations. 
       The assistant vice president of clinical regulatory (AVP Clinical Regulatory) was the project 
lead who was responsible for analyzing the opioid regulations and develop the opioid policy 
along with providing project oversight. The policy manager, who reports to AVP Clinical 
Regulatory, downloaded the federal, state, and local opioid regulations. The opioid regulations 
were searched using Google Chrome search engine with the following keywords - “opioid 
regulations”, “opioid laws”, “opioid statutes”,  and “opioid guidelines”. Additionally, state health 
departments, state or local drug enforcement agencies, and federal Drug Enforcement Agency 




were searched for opioid regulations. The downloaded opioid regulations were deposited in a 
Microsoft Office 365 SharePoint spreadsheet on the company’s intranet. The purpose of using 
this software tool was to provide open access for employees for ease of collaboration on the 
project. SharePoint software has the capability to alert the document owner every time an update 
is made. The project lead accessed the SharePoint repository at a minimum once a week to 
review newly added information, and extract opioid regulations related to opioid prescription, 
required education for patients who are prescribed opioids, and medication disposal. 
           Evaluation/Analytic Plan: The policy manager was responsible for downloading the 
opioid regulations several times a week. During weekly review, AVP Clinical Regulatory 
ensured that new and/or updated opioid regulatory information has been added to the SharePoint 
repository. The weekly review began after this DNP project proposal was approved by the Yale 
school of nursing committee in Summer 2020. 
Aim 2: Appraise and synthesize opioid regulations to develop a hospice practice specific 
opioid policy. 
       The KTA Process Framework was utilized that aligned well with the scope and purpose of 
this project. Under the framework, opioid laws and regulations were synthesized. The gathered 
knowledge was transferred into actionable system-level policy for hospice practice. After 
extracting the opioid regulations related to opioid prescription, required education for patients 
who are prescribed opioids, and medication disposal for each state, the AVP Clinical Regulatory 
conducted a comparative analysis of federal, state, and local regulations. The purpose of this 
comparison was to identify similarities and differences among federal, state, and local 
regulations. From the information extracted, the AVP Clinical Regulatory developed a draft 
Opioid Management policy. An umbrella policy was developed for all those states among which 




there are no differences in opioid regulations (Appendix B). State specific opioid policy was 
created for the states with variabilities in opioid regulations that cannot be reconciled with the 
umbrella opioid policy due to different or additional mandates. The draft policies were sent for 
review and comments to the key stakeholders in the interdisciplinary opioid project team. The 
interdisciplinary opioid project team consisted of the hospice medical director, assistant vice 
president of clinical regulatory, policy manager, internal counsel, operations manager, & clinical 
manager. The review and comments were sought from the hospice medical director, internal 
counsel, & clinical manager. Internal counsel provided guidance if an external counsel review 
was needed. Once a month, the interdisciplinary opioid project team meeting met via phone 
conference call. The purpose of this meeting was to address concerns, seek feedback, and 
finalize policy. The recommendations from “Policy and Procedure Development Guidelines” 
(Irving, 2014, para. 10) are listed under Appendix C and were used to develop the policy. The 
policy was finalized by July 2020, and sent to hospice policy committee meeting for approval for 
circulation. The hospice policy committee is a standing committee that meets monthly to approve 
or reject requests for new policies, updated policies, and archiving policies.  
           Evaluation/Analytic Plan: Project lead accessed the SharePoint repository once a week 
to review opioid regulations, and appraise them to create policy themes. The interdisciplinary 
core team met once a month to assess the progress of & provide recommendations for opioid 
policy content and theme development. These meetings were held monthly until August 2020,  
then quarterly thereafter. The policy manager was responsible for sending timely meeting invites 
and meeting minutes following the meeting. The stakeholders, consisting of senior operations 
executives, were appraised monthly of the policy development. 
 




Aim 3: Implement the policy system-wide. 
       After policy committee approval in July 2020, the policy manager scheduled meetings with 
a second team, the interdisciplinary implementation team. At this meeting, AVP Clinical 
Regulatory shared the policy’s operational & documentation requirements with the 
interdisciplinary implementation team. The interdisciplinary implementation team was 
responsible for implementing the finalized policy system-wide, and consist of an operations 
manager, a clinical manager, an education manager, & EMR clinical analyst.  
       The opioid  policy requirements were to be embedded into operational processes and 
electronic medical record (EMR) documentation software before system-wide policy 
implementation & education can occur. Under AVP Clinical Regulatory oversight, the EMR 
clinical analyst designed the policy updates to be embedded into the EMR software by first week 
of August 2020. The opioid documentation in EMR software was designed for convenience of 
data extraction to evaluate physicians, nurse practitioners, and nurses’ compliance with the 
policy. The major EMR documentation categories listed were type of opioid prescription (long or 
short acting), clinician communication with patient, non- pharmacological & alternative options, 
patient education, opioid reconciliation, and opioid disposal. Appendix D contains a template of 
the EMR documentation categories. The EMR clinical analyst was responsible for updating the 
EMR operations manual including the policy and documentation updates. 
       Under AVP Clinical Regulatory oversight, the education manager designed policy education 
to be disseminated to physicians, nurse practitioners, nurses, nurse managers, and care center 
directors. This policy education included policy updates and EMR documentation specifications. 
Prior to system-wide policy implementation, the AVP Clinical Regulatory pre-informed affected 
personnel of the upcoming new policy. The mandatory Web-Ex policy education followed by an 




e-mail policy update blast was used for policy dissemination, in addition to clinical newsletter, 
an online learning management system (self-education session), & onsite education sessions by 
the care center director during a weekly staff meeting (Appendix E). The attendees had the 
option to send their questions to a group email address at ~clinical.regulatory@Amedisys.com. 
This email is delivered to the policy manager and AVP Clinical Regulatory.  
       The final Opioid Management policy was planned for system-wide implementation in the 
third and fourth quarters of 2020. The system-wide dissemination & implementation was 
planned for a 17 week period in three waves, at the 6 weeks, 7 weeks, and 4 weeks mark.  
           Evaluation/Analytic Plan: An attendance report was extracted from the web-ex and 
learning management system, and the care center director was responsible for keeping 
attendance for the on-site policy education sessions. The operations manager reported for 
attendance compliance update to the core team after each mandatory Web-Ex policy education 
session. The plan was to provide a one on one education by the care center administrator for 
clinicians who were not able to attend the Web-Ex policy education. However, due to COVID-19 
restrictions, those clinicians were assigned a self-learning course via online learning platform. 
The care center administrator was responsible for keeping attendance for the mandatory Web-Ex 
policy education sessions.  
Aim 4: Develop a process to evaluate clinician’s adherence to the opioid policy. 
       To hardwire the new expectations, clinicians were encouraged and recognized for opioid 
policy/protocol compliance. On the internal Yammer page, at standup morning meetings, or 
during interdisciplinary meetings, a shout out was posted for clinician and/or a care center 
staying compliant with opioid policy/protocol. Clinical leaders were encouraged to seek 
feedback from clinicians at point of care about what’s working and what’s not, such as, ease of 




policy/protocol use, any hinderance, any feedback for protocol workflow improvement. 
Additionally, the plan was for change champions (peer) and supervisors to seek feedback during 
ride-along or competency check or staff luncheons, however due to COVID-19 restrictions, all 
feedback was sought via phone. 
       Beginning September 2020, a weekly EMR report, for each care center, was produced & 
reviewed by policy manager to assess compliance with policy implementation. The results were 
shared with core team. The purpose of this report review was to assess percentage of clinician 
compliance with the EMR documentation.  
           Evaluation/Analytic Plan: The goal was to achieve a 100% clinician compliance with 
state and federal regulations. For the care centers falling behind the goal, the plan was to put 
them on a two-part performance improvement plan. Part one was a root cause analysis (RCA) of 
non-compliance to determine if it’s due to a system issue, a lack of understanding, or clinician 
negligence. Based on the results of RCA, re-education of clinicians was to be conducted.  
      Pre- and post-policy implementation, a comparison review of opioid-related events was 
conducted. The opioid-related events include prescriber failure to follow opioid prescription 
protocol, clinician failure to follow opioid-related patient education policy, clinician failure to 
follow opioid disposal protocol, and clinician failure to follow opioid medication reconciliation 
during every home visit to the patient. A baseline was established using opioid-related events 
during the calendar year 2019-2020. A robust goal was set of at least a 50% reduction in opioid-
related events at the end of first 2 weeks of training, at least 75% reduction after next 2 weeks of 
training, and sustain at least 85% reduction after the next 4 weeks of training. 
 
 





       A visualization of the detailed project timeline for the actualization of this DNP project can 
be found in Appendix F. Zoom, phone, or in-person meetings with DNP project advisor, Dr. 
Marianne Davies began in October 2018, with discussions about project topic selection, and 
continued with DNP project advisor, Professor Mary Ann Camilleri. The project proposal was 
submitted in December 2019. To seek project proposal approval, a defense presentation was 
scheduled in Summer of 2020 in front of the proposal approval committee of Yale School of 
Nursing. The review of opioid regulations to draft the opioid policy began in Summer 2020.  
       A policy manager was hired in April 2019 to manage opioid regulation information 
downloads and create the Sharepoint regulations repository. There was a total of two separate 
teams working under this project - the Interdisciplinary Project team and Interdisciplinary Project 
Implementation team. Both teams were created in Spring of 2020. The opioid policy was created 
by mid-July 2020. Following policy creation, the implementation team began planning for policy 
education, disseminations, & evaluation. The education and EMR documentation template build 
was completed by end of July 2020. The policy implementation, including education & 
dissemination of information was completed by end of Nov 2020. Attendance to policy 
education sessions was tracked throughout the policy implementation phase. Beginning 
September 2020, data from the EMR documentation compliance report was analyzed for 
outcome evaluation. The proposed completion date of the project was December 2020. The 
proposed date to have a manuscript submitted to a peer-reviewed journal or an abstract submitted 
to a professional conference was by January 31, 2021. The abstract has been accepted for 46th 
Biennial Convention (6-10 November 2021) of Sigma Theta Tau International Honor Society of 
Nursing (Sigma). 





       Nursing education at the Doctorate of Nursing Practice level prepares the advanced practice 
nurse (APN) to integrate evidence into practice and shape local and global views of nursing. This 
DNP project allowed me to achieve my goals of working as a healthcare policy leader in the 
hospice and palliative care setting, becoming involved in policy analysis, policy decisions, and 
contributing to safe patient practices. Under the mentorship of end of life care and cancer 
experts, and legal and risk management experts, I implemented the project, analyzed the results, 
and made recommendations for practice and, if appropriate, future research. 
       The leadership immersion for this DNP project began in July 2020 and continued on to 
Spring of 2021. The sponsor of this project was VP Clinical Risk. The hospice & palliative care 
expert corroborating in the project was executive medical director and SVP Clinical Operations, 
and legal expert corroborating in the project was VP Legal. The goals of leadership immersion 
were engagement, collaboration, education, implementation and compliance. The 
interdisciplinary project teams’ monthly meetings and ongoing email communications enabled 
engagement with the organization’s clinical operations and education leaders. The 
interdisciplinary project team meetings held to review opioid regulations for opioid policy draft 
helped facilitate building knowledge through subject-matter expert feedback and understanding 
policy impact on clinical operations and practice. Collaboration with the project implementation 
team facilitated planning for system-wide policy dissemination and evaluating compliance 
thereafter. The implementation team members included health information technology, training, 
and clinical operations experts. A systematic dissemination and evaluation plan built with this 
implementation team’s help provided consistent policy messages to the clinicians. 
  






      By end of November 2020, 100% of the hospice nurses, nurse practitioners and physicians 
received education on umbrella opioid medication policy, and state specific guidance. The 
system-wide dissemination & implementation was completed over a 4 week period in three 
waves (Figures 9 & 10 ). At the end of 1st 2 weeks of policy implementation, 11 states in 
northeast region had implementation completed. Likewise, at the end of next week, 15 additional 
states in south, Midwest & southeast, and at the end of final week, 9 additional states in south & 
west region had implementation completed. Due to social distancing restrictions uring COVID-
19 public health emergency, all policy education was provided remotely via Web-Ex or online 
learning management platform. 
 
Figure 9: Regions covered under policy dissemination waves schedule 
 





 Figure 10: States completed by Wave schedule 
 
      Beginning December 1, 2020, the clinician compliance with opioid policy was monitored at 
the end of every week. By end of first week of December 2020, through their documentation in 
EMR, 100% of the clinicians in 28.5% (10 states) of all 35 states demonstrated 100% 
compliance with state and federal regulations (Figure 11). Sharing this result via internal 
Yammer page and highlighting states that had achieved compliance created a cadence of 
demonstrated compliance in another 22 states. By the end of third week of December 2020, 
100% of the clinicians in 91% (32 states) of all 35 states demonstrated 100% compliance with 
state and federal regulations. These 32 states continued to maintain compliance with the umbrella 

































         
Figure 11: Clinician compliance in 4 weeks 
 
      Only 40% clinicians in remaining 3 states achieved compliance by first week of January 
2021. A root cause analysis was conducted to figure out the reason for non-compliance. A user 
complacency to adopt documentation practices as dictated by the policy and a lack of supervision 
by the immediate supervisor were found to be the root cause of non-compliance with the policy. 
A re-education was provided to enforce policy compliance. 
      Pre- and post-policy implementation, a comparison review of opioid-related events was 
conducted. In each of the opioid-related events category, at least 50% reduction was seen. In 
opioid disposal category 66.66% and in medication reconciliation category 55.55% reduction 
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Clinician failure to follow opioid medication 






        
       Table 1: A comparison review of opioid-related events 
 
Discussion 
      This project was conducted at meso and macro levels in a multi-state multilevel organization. 
Since the implementation of opioid policy was at a multi-state, multi-site organization, it was 
important to take into account barriers and facilitators to the success of the implementation. 
Barriers to policy implementation and adoption were activation of an emergency preparedness 
plan causing operational disruption, a competing regulatory requirement, and a technology 
breakdown. Due to COVID-19 public health emergency (PHE), the organizational resources 




were diverted causing a delay of 6 months from the original timeline. In September 2020, a new 
hospice regulation about election of hospice benefit addendum was rolled out to be compliant 
with Medicare mandate. This competing regulatory requirement caused significant delay in 
opioid policy dissemination. The timeline was postponed to November 2020, and length of time 
available to complete policy dissemination was shortened to one third of the original timeframe 
of 17 weeks. 
      On the other hand, identifying change champions within the organization favorably enabled 
and facilitated systemwide implementation, and effective adoption, and continued compliance 
with the policy. The supervisors engaged in enforcing the policy guidance conducted continued 
monitoring of clinician documentation in EMR, and provided real time correction. Although the 
preparation was done to provide policy education via multiple modes, due to COVID19 PHE 
social distance restrictions, in-person sessions were cancelled. All policy education sessions were 
moved to broadcast style intranet platform or pre-recorded modules on company’s learning 
management system. The education and operations teams were willing and quick to adapt to 
mode of delivery and timeline changes. 
      A robust goal was set of at least a 50% reduction in opioid-related events at the end of first 2 
weeks of training, at least 75% reduction after next 2 weeks of training, and sustain at least 85% 
reduction after the next 4 weeks of training. A reduction of  >50% was seen but couldn’t achieve 
75% reduction goal in the observed timeframe. A longer length of observation period is needed 









       “Large healthcare institutions may be the most complex in human history, and even small 
healthcare organizations are barely manageable.” ~Peter Drucker  
       Increasingly, the care of advanced illness patients, palliative or hospice care, is being moved 
to ambulatory settings. It is imperative that Quality and Safety initiatives are in place in the 
ambulatory setting, in the same respect as those in place in acute care settings. It also imperative 
that nursing healthcare policy leaders be prepared in policy analysis, change processes, business, 
etc. to assure safe patient care. The implications of this DNP project are two-fold. First, this 
project seeks is to assist hospice practices to meet regulatory compliance by making available the 
most current legal and regulatory information to guide institutional policy and daily patient care 
practices. In doing so, the risks associated with using outdated information, including 
noncompliance with legal and regulatory requirements,  will be mitigated. Second is to promote 
patient safety by system-wide implementation of the policy. This will enable uniform 
practitioner practice and reduce harm to the patient associated with variable practices within a 
specific site location or region. If the company fails to comply with applicable laws and 
regulations, it could be subjected to liabilities, including criminal penalties, civil penalties 
(including the loss of our licenses to operate one or more of our businesses) and exclusion of a 
facility from participation in the Medicare, Medicaid, and other federal and state health care 
programs. If any of our facilities were to lose its accreditation or otherwise lose its certification 
under the Medicare and Medicaid programs, the facility is at risk for loss of reimbursement from 
the Medicare and Medicaid programs and other payors (Annual Reports, n.d.). Failure to comply 
with opioid practice regulations could result in a disciplinary action against a prescriber or 
clinician, including but not limited to probation, limitation, denial, fine, suspension, revocation 




or permanent revocation of the professional practice license (MSMS, 2018). Additionally, failure 
to comply with opioid practice regulations may place patients at risk for medical error (Dy, 
2016) or impair accessibility to opioids even when medically appropriate (Fehlberg, Broyles, 
Wu, & Halpern, 2018).  
      This DNP project has applicability to further compliant opioid practice in a variety of care 
settings nationwide. Especially in the current environment of large system, multistate practice, an 
organization  may be subject to similar or conflicting laws and regulations from state to state. 
The framework developed in this project, an umbrella policy and identified tentacle policies with 
state specific variation maintained through a centralized system, offers an efficient strategy for 
multistate providers to ensure compliance.  This system advances the quality of care by 
prescribing providers.  To further the uptake of this approach for broader impact,  I plan to seek 
publication in two nationally recognized journals, the Journal of Hospice & Palliative Nursing of 
the Hospice & Palliative Nurses Association, and Journal for Healthcare Quality of the National 
Association for Healthcare Quality. For dissemination to the hospice industry,  I plan present at 
the National Association for Home Care & Hospice and the National Hospice and Palliative Care 
Organization conferences. In addition, I would like to explore with national nursing, hospice, and 
patient safety organizations an opportunity to do a workshop, a teleconference, or a webinar. 
Whether by synchronous or pre-recorded for asynchronous learning, this approach would further 
expand the accessibility of this framework for compliant opioid practice. 
Limitations 
      The presence of COVID-19 PHE created a heightened awareness for anticipating and 
planning for failures or interruptions in the project before an adverse event occurs. Failure Mode 
and Effects Analysis (FMEA) is a structured way to identify and address potential problems 




before they occur. If a FMEA was conducted before the project kicked off, resource allocation 
disruption, deviation of resources, a backup training mode, etc. could have been anticipated and 
planned for. 
Conclusion 
      A review of current opioid regulations and development of opioid prescription, use, patient 
education, and disposal policies and practices will provide clarity to hospice and palliative care 
practitioners engaged in care of EOL advanced cancer and non-cancer patients. These policies 
will guide the hospice clinicians of their role and responsibility while caring for patients who are 
prescribed opioids at EOL. 
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Aim 2: Development of opioid policy and clinical documentation protocol 
  





Policy and Procedure Development Guidelines 
(Reprinted from Policies and Procedures for Healthcare Organizations: A Risk Management 
Perspective. Retrieved from https://www.psqh.com/analysis/policies-and-procedures-for-
healthcare-organizations-a-risk-management-perspective/ December 2019) 
Recommendation Rationale 
Define all terms used within the policy. It is useful to put these definitions at the beginning 
of the policy. If terms are not defined, they may be 
misconstrued by staff and/or when later scrutinized 
by plaintiff lawyers. 
Refrain from using superlative words or statements, 
such as: 
a) Highest, safest, best (level of care) 
b) Assure, ensure (preferable to use “to promote”) 
The presence of superlative adjectives is sometimes 
alleged by plaintiff lawyers to be a “guarantee” of a 
certain outcome. 
Exercise caution when using absolutes such as 
shall, must, or do not unless intended as such. 
Many circumstances allow for clinical judgment.  
Select a simple, recognizable name for the policy.  
Naming a policy “Chain of Command Policy” is 
preferable to naming it, “Disagreement over patient 
care.” Staff will have an easier time locating a policy 
with a familiar name. 
Combine separate policies on the same subject into 
one policy. If it becomes lengthy, create a table of 
contents so the user can easily locate specific 
sections. 
For instance, the policy for medical screening 
examinations, transfer in/out, reporting EMTALA 
violations, etc. should appear in a single EMTALA 
policy.  
Use the active rather than the passive voice when 
writing specific procedure action steps.  
Passive voice: “The specimen container should be 
labeled.” 
Active voice: “Place a label on the specimen 
container.” 
Ensure responsibility for carrying out each action 
step is explicitly stated, not implied. 
Each section should have two columns: the one on 
the left outlines the action to be taken, and the one 
on the right says who is responsible for carrying out 
each step. 
Obtain the sign-off of all stakeholders (domain 
leaders) affected by each policy, as well as each 
oversight committee or entity that reviewed and 
approved of it (e.g.. Medical Executive Committee 
[MEC]).  
It is not uncommon to see “nursing” policies that 
outline actions an independently credentialed 
physician is expected to take. Any policy that 
outlines medical staff responsibilities warrants their 
input during development and subsequent reviews. 
Medical staff members also need to know where to 
access those policies.  
Require each approving entity or person to sign off 
on each individual policy. In years past, paper policy 
manuals often included a “cover sheet” as a sign-off 
page, which showed the date of approval and 
signature of the approving leader, in lieu of him/her 
signing each policy. 
Cover sheets for sign off are not effective for 
electronic documents.  





Note the date of origin of the policy and each 
subsequent review or modification date within the 
body of the policy, typically on the last page near the 
sign-offs:  
Date of origin: ____ 
Review date: ____ 
Review date: ____ 
Pay particular attention to how the approvals for 
subsequent policy updates are documented in the 
electronic version of the policy.  
Establish naming and numbering conventions for 
use across the health system. 
Number all pages, reflecting the total number of 
pages as well: page 1 of 5, 2 of 5, etc. Put the policy 
title/number in the header of each page. 
Note other policies on a similar subject that may be 
useful at the end of the policy, for cross-reference 
purposes. Incorporate any related form(s) or 
computer screen images referred to in a policy 
For example, the disclosure policy should cross-
reference adverse event reporting policy, the patient 
complaint/grievance policy, and the bill 
hold/adjustment policy. Also for example, the 
EMTALA transfer form should be a part of the 
EMTALA policy. 
Cite specific federal or state statute(s) that are the 
basis for a policy or procedure with any other 
references. 
It may also be helpful to put a URL link to those 
statutes. 
At the end of the document, note evidence-based 






Some organizations simply place a list of resources 
as an attachment to each policy, so that it is not a 
part of the actual, page-numbered policy document.  
Noting the referenced resources in each policy has 
both advantages and disadvantages. The 
advantage is that readers are aware of a 
professional source for more information on that 
subject. Another advantage is that it demonstrates 
the policy was developed with awareness of 
recognized professional guidelines and evidence-
based best practices. However, potential risks arise 
when: a) the organization’s policy differs from the 
cited professional guidelines or omits some key 
element noted in those guidelines; b) If the cited 
professional guideline is updated following issuance 
of the policy, and the organization has not updated 
the policy accordingly.  
Doing so means that if the organization has to 
produce the policy during discovery, the list of 
resources need not be turned over, since it “was not 
part of the policy itself”. 
Avoid under-specifying: Put all essential elements in 
the policy.  
For instance, stating that “X action shall be taken” 
does not specify which staff member is responsible 
for carrying out the task. 
Avoid developing policies that outline actions that 
are more rigorous than the typical “standard of 
care.” 
If a hospital implements a policy that goes 
beyond what is the prevailing practice in the 
industry, the organization will be held to the higher 
standard. 
Use caution when approving a policy on a specific 
topic or practice that simply states that staff shall 
Doing this implies: a) the cited book is the most 
updated authoritative source on that subject; b) the 





adhere to the practices outlined in “ABC Textbook” 
(and does not outline the organization’s own steps). 
Citing a reference as the policy may be appropriate 
in a narrow range of situations. For example, the 
American College of Radiology publishes an 
evidence-based, comprehensive “Use of Contrast 
Media Manual” with regular updates. Rather than 
develop its own policies on this subject (which would 
likely be shorter and oversimplified when compared 
to this manual), a hospital-based radiology 
department may wish to endorse the staff’s use of 
this manual, with the proviso noted to the right. 
responsible domain leaders have reviewed the book 
from cover to cover and have “endorsed” all of its 
contents; c) staff members have ready access to 
that resource (at all times); and d) there is a process 
in place to monitor when the ACR issues a revised 
version of this manual, so the organization does not 














EMR Opioid Documentation Template 
Opioid documentation in EMR software will be designed for convenience of data extraction to 
evaluate physicians, nurse practitioners, and nurses for compliance with the policy. The major 
EMR categories will be: 
• Type of opioid prescription 
o Long acting 
o Short acting 
• Case manager nurse, patient/family caregiver, & prescriber 
communication 
o Yes 
• Communication note 
o No 
• Non-pharmacological & alternative options 
o Offered 
• Documentation of options offered & outcome 
o Not offered 
• Document why not offered 
• Patient education 
o Yes 
• Communication note 
o No 
• Describe why? 
• Opioid Reconciliation 
o Yes 
• Communication note 
o No 
• Describe why? 
o Not applicable 
• Opioid disposal 
o Yes 
• Communication note 
o No 
• Describe why? 
o Not applicable 
 
  
































Timeline of the DNP Project 
 
Task Start Date End Date Duration 
Meetings with DNP Project Advisor (ongoing) 10/1/18 1/31/21 485 
Create position & Hire Policy Manager 1/1/19 4/1/19 90 
Download Federal Opioid Regulations 12/17/19 1/17/20 30 
Download State & Local opioid regulations 12/17/19 1/17/20 30 
Build Repository Framework on Sharepoint 11/11/19 11/18/19 7 
Create automatic alerts to be sent to Project lead of deposited regulations 11/18/19 11/20/19 2 
Build Interdisciplinary Project teams 1/20/20 3/20/20 59 
Review federal opioid regulations 6/1/20 6/30/20 30 
Review State & local opioid regulations 6/1/20 6/30/20 30 
Develop policy themes & draft an opioid policy 7/1/20 7/20/20 20 
Interdisciplinary opioid project team meetings - Monthly 3/20/20 11/20/20 240 
Finalize Opioid Policy 7/25/20 8/07/20 14 
Amedisys Policy Committee Approval  8/07/20 8/07/20 1 
Update EMR documentation template 8/7/20 8/31/20 25 
Update Operations Process Manual 8/7/20 8/31/20 25 
Design & Build Policy Education  8/7/20 8/31/20 25 
Send E-mail blast of policy implementation 8/15/20 8/15/20 1 
Web-Ex policy education sessions 9/1/20 11/30/20 61 
Online LMS policy education sessions 9/1/20 11/30/20 61 
On-site policy education 9/1/20 11/30/20 61 
Web-Ex attendance (Outcome Evaluation) 9/1/20 11/30/20 61 
Online LMS policy education attendance (Outcome Evaluation) 9/1/20 11/30/20 61 
On-site policy education attendance (Outcome Evaluation) 9/1/20 11/30/20 61 
EMR Compliance Report (Outcome Evaluation) 9/30/20 12/5/20 66 
Manuscript Submitted to Peer-Reviewed Journal or Conference 1/1/21 1/31/21 31 
 
